Related Experiment Videos
Summary
Extracutaneous mycosis fungoides (ECMF) survival is improved with early diagnosis and topical therapies. Achieving a complete response (CR) and using electron beam treatment significantly impacts patient outcomes in advanced disease.
Area of Science:
- Dermatology
- Oncology
- Clinical Medicine
Background:
- Extracutaneous mycosis fungoides (ECMF) represents advanced disease stages.
- Limited data exists on prognostic factors and optimal management for ECMF.
Purpose of the Study:
- To review the clinical course and survival of patients with ECMF.
- To identify significant prognostic factors and effective therapeutic strategies for ECMF.
Main Methods:
- Retrospective review of 40 patients with histologically confirmed ECMF.
- Analysis of various topical, regional, and systemic therapies.
- Multivariate analysis to identify significant prognostic factors for survival.
Main Results:
- Median survival for the entire group was 14.5 months.
- Complete response (CR) was achieved by 28% of patients, with a median survival of 21 months.
- Significant prognostic factors included ECMF at presentation and use of topical therapy, particularly electron beam treatment.
Conclusions:
- Early diagnosis of ECMF and prompt initiation of topical therapies are crucial for improved outcomes.
- Achieving a complete response is a key determinant of prolonged survival.
- Cyclophosphamide, vincristine, prednisone (CVP) and cyclophosphamide, vincristine, prednisone, and bleomycin (COP-Bleo) showed efficacy as chemotherapeutic regimens.